Is BMY or GRFS more undervalued in 2026?

CirclFi compares Bristol-Myers Squibb Company (BMY) and Grifols, S.A. (GRFS) using 13 institutional-grade valuation models. BMY has a Quality of Company score of 10.0/10 while GRFS scores 1.7/10.

Which is a better buy — BMY or GRFS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BMY and GRFS valuations compare?

BMY at $56.91 and GRFS at $7.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BMY vs GRFS Valuation Comparison 2026 — Intrinsic Value Analysis

BMY

Drug Manufacturers - General

Bristol-Myers Squibb Company

Quality

10.0

out of 10

Value Trap

SAFE

Price

$56.91

Last close

Models

12/13

Active

GRFS

Drug Manufacturers - General

Grifols, S.A.

Quality

1.7

out of 10

Value Trap

—

Price

$7.98

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	BMY Fair Value	BMY Upside	GRFS Fair Value	GRFS Upside
Bayesian DCF	Intrinsic	$123.15	+116.4%	$2.36	-70.5%
Earnings Power Value	Intrinsic	$52.56	-7.6%	$3.00	-62.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BMY vs GRFS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BMY vs GRFS — Which Stock Is More Undervalued?

BMY scores higher with a 10.0/10 quality rating vs GRFS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bristol-Myers Squibb Company (BMY) and Grifols, S.A. (GRFS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BMY currently trades at $56.91 with a QOC of 10.0/10, while GRFS trades at $7.98 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).